TY - JOUR T1 - Population-wide evolution of SARS-CoV-2 immunity tracked by a ternary immunoassay JF - medRxiv DO - 10.1101/2020.05.31.20118554 SP - 2020.05.31.20118554 AU - Marc Emmenegger AU - Elena De Cecco AU - David Lamparter AU - Raphaël P. B. Jacquat AU - Daniel Ebner AU - Matthias M. Schneider AU - Itzel Condado Morales AU - Dezirae Schneider AU - Berre Doğançay AU - Jingjing Guo AU - Anne Wiedmer AU - Julie Domange AU - Marigona Imeri AU - Rita Moos AU - Chryssa Zografou AU - Chiara Trevisan AU - Andres Gonzalez-Guerra AU - Alessandra Carrella AU - Irina L. Dubach AU - Catherine K. Xu AU - Georg Meisl AU - Vasilis Kosmoliaptsis AU - Tomas Malinauskas AU - Nicola Burgess-Brown AU - Ray Owens AU - Stephanie Hatch AU - Juthathip Mongkolsapaya AU - Gavin R. Screaton AU - Katharina Schubert AU - John D. Huck AU - Feimei Liu AU - Florence Pojer AU - Kelvin Lau AU - David Hacker AU - Elsbeth Probst-Müller AU - Carlo Cervia AU - Jakob Nilsson AU - Onur Boyman AU - Lanja Saleh AU - Katharina Spanaus AU - Arnold von Eckardstein AU - Dominik J. Schaer AU - Nenad Ban AU - Ching-Ju Tsai AU - Jacopo Marino AU - Gebhard F. X. Schertler AU - Jochen Gottschalk AU - Beat M. Frey AU - Regina Reimann AU - Simone Hornemann AU - Aaron M. Ring AU - Tuomas P. J. Knowles AU - Ioannis Xenarios AU - David I. Stuart AU - Adriano Aguzzi Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/02/2020.05.31.20118554.abstract N2 - Serological assays can detect anti-SARS-CoV-2 (SARS2) antibodies, but their sensitivity often comes at the expense of specificity. Here we used a Ternary Automated Blood Immunoassay (TRABI) to assess the IgG response against SARS2 in 3’815 prepandemic plasma samples and 126 virologically and/or clinically confirmed COVID-19 samples. Posterior probabilities were calculated from 3×8 measurements of logarithmically diluted samples against the ectodomain and the receptor-binding domain of the spike protein and the nucleoprotein. We then performed 429’624 assays on 17’901 blood samples from patients of the University Hospital Zurich and from healthy blood donors. We found seropositivity in 44 of 8’591 patients and in 26 of 5’388 blood donors from December 2019 to May 2020. Western blotting confirmed seropositivity in COVID samples but in none of the prepandemic samples. Solution-equilibrium measurements revealed immunodominant antibodies with nanomolar affinity in COVID samples, whereas prepandemic plasma showed lower affinities despite similar titers for individual SARS2 antigens. Hence, TRABI identifies seropositive individuals in large unselected cohorts, discriminates between SARS2 immunity and low-affinity crossreactivity, and is therefore suitable for large-scale nationwide screening campaigns.Competing Interest StatementTPJK is a member of the board of directors of Fluidic Analytics. AA is a member of the board of directors of Mabylon AG which has funded antibody-related work in the Aguzzi lab in the past. All other authors declare no competing interests.Funding StatementInstitutional core funding by the University of Zurich and the University Hospital of Zurich to AA, as well as Driver Grant 2017DRI17 of the Swiss Personalized Health Initiative to AA. The robotic rig was acquired with a R'Equip grant of the Swiss National Foundation to AA. Screening methodologies had been developed thank to the support of an Advanced Grant of the European Re-search Council and a Distinguished Scientist Award of the Nomis Foundation to AA. Funding by grants of Innovation Fund of the University Hospital Zurich to AA, AvE, DS, EPM, ME, and OB. Access to the Creoptix WAVEsystem was kindly provided by Creoptix AG. Waedenswil, CH. This work was supported by ETH Research Grant ETH-23 18-2 and a Ph.D. fellowship by Boehringer Ingelheim Fonds to KS. Raphael Jacquat acknowledges funding by the EPSRC for Doctoral Training in Sensor Technologies and Applications (grant EP/L015889/1). ICM acknowledges funding by the Swiss Government FCS. Carlo Cervia was funded by a Swiss Academy of Medical Sciences fellowship (#323530-191220). GFXS was supported by an COVID-19 Emergency Fund of the Director of PSI. TM is supported by Cancer Research UK grants C20724/A14414 and C20724/A26752 to Christian Siebold (Oxford). Oxford work was supported by the MRC and Chinese Academy of Medical Sciences Innovation Fund for Medical Science, China Grant 2018-I2M-2-002. GRS is supported as a Wellcome Trust Senior Investigator (grant 095541/A/11/Z) and receives funding from the National Institute for Health Research Biomedical Research Centre Funding Scheme.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Kantonale Ethikkommission (KEK) ZuerichAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data underlying this study will be made available upon reasonable request. The biobank samples are limited and were exhausted in several instances. Therefore, while we will make ef-forts to provide microliter amounts of samples to other researchers, their availability is physically limited. ER -